Drug Type Small molecule drug |
Synonyms 100907, M 100907, M-100907 + [5] |
Target |
Mechanism 5-HT2A receptor antagonists(Serotonin 2a (5-HT2a) receptor antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Molecular FormulaC22H28FNO3 |
InChIKeyHXTGXYRHXAGCFP-OAQYLSRUSA-N |
CAS Registry139290-65-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Volinanserin | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus, Type 2 | Phase 3 | US | 01 Apr 2007 | |
Diabetes Mellitus, Type 2 | Phase 3 | AR | 01 Apr 2007 | |
Diabetes Mellitus, Type 2 | Phase 3 | AU | 01 Apr 2007 | |
Diabetes Mellitus, Type 2 | Phase 3 | AT | 01 Apr 2007 | |
Diabetes Mellitus, Type 2 | Phase 3 | BE | 01 Apr 2007 | |
Diabetes Mellitus, Type 2 | Phase 3 | BR | 01 Apr 2007 | |
Diabetes Mellitus, Type 2 | Phase 3 | CA | 01 Apr 2007 | |
Diabetes Mellitus, Type 2 | Phase 3 | CL | 01 Apr 2007 | |
Diabetes Mellitus, Type 2 | Phase 3 | CO | 01 Apr 2007 | |
Diabetes Mellitus, Type 2 | Phase 3 | CZ | 01 Apr 2007 |